================================================================================ UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15 (d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of Earliest Event Reported): July 15, 2004 Medicis Pharmaceutical Corporation (Exact Name of Registrant as Specified in Charter) Delaware 0-18443 52-1574808 (State or Other Jurisdiction of (Commission File Number) (IRS Employer Incorporation) Identification No.) 8125 North Hayden Road Scottsdale, Arizona 85258-2463 (Address of Principal (Zip Code) Executive Offices) Registrant's telephone number, including area code: (602) 808-8800 N/A ------------------------------------------------------- (Former Name or Former Address, if Changed Since Last Report) ================================================================================ Item 5. Other Events On July 15, 2004, Medicis Pharmaceutical Corporation (the "Company") issued a press release announcing that it had entered into an exclusive license agreement with Q-Med AB ("Q-Med") to market, distribute, sell and commercialize in the United States and Canada Q-Med's product currently known as SubQ(TM). A copy of the Company's press release is attached hereto as Exhibit 99.1. Item 7. Financial Statements and Exhibits (a) Financial Statements of Business Acquired. Not Applicable. (b) Pro Forma Financial Information. Not Applicable. (c) Exhibits. 99.1 Copy of press release, dated July 15, 2004, issued by Medicis Pharmaceutical Corporation SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this Report to be signed on its behalf by the undersigned hereunto duly authorized. MEDICIS PHARMACEUTICAL CORPORATION (Registrant) Date: July 15, 2004 /s/ Mark A. Prygocki, Sr. ------------------------------------------ Name: Mark A. Prygocki, Sr. Title: Executive Vice President, Chief Financial Officer, Corporate Secretary and Treasurer EXHIBIT INDEX EXHIBIT NUMBER DESCRIPTION ------ ----------- 99.1 Copy of press release, dated July 15, 2004, issued by Medicis Pharmaceutical Corporation